Literature DB >> 16272279

A selective role for the TNF p55 receptor in autocrine signaling following IFN-gamma stimulation in experimental autoimmune uveoretinitis.

Claudia J Calder1, Lindsay B Nicholson, Andrew D Dick.   

Abstract

IFN-gamma stimulates macrophage activation and NO production, which leads to destruction of the retina in experimental autoimmune uveoretinitis. In this study, we investigate the mechanism of disease resistance in TNF p55 receptor-deficient animals. We show that although T cell priming is relatively unaffected, macrophages lacking the TNF p55 receptor fail to produce NO following IFN-gamma stimulation because of a requirement for autocrine TNF-alpha signaling through the TNF p55 receptor. In contrast to the impaired activation of NO synthesis, MHC class II up-regulation was indistinguishable in wild-type and TNFRp55-/- mice stimulated with IFN-gamma. These defects could be overcome by stimulating macrophages with LPS. Together, these results show that selected aspects of IFN-gamma activation are controlled by autocrine secretion of TNF-alpha, but that this control is lost in the presence of signals generated by pathogen-associated molecular patterns recognizing receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272279     DOI: 10.4049/jimmunol.175.10.6286

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  Interplay between innate and adaptive immunity in the development of non-infectious uveitis.

Authors:  François Willermain; James T Rosenbaum; Bahram Bodaghi; Holly L Rosenzweig; Sarah Childers; Travis Behrend; Gerhild Wildner; Andrew D Dick
Journal:  Prog Retin Eye Res       Date:  2011-11-22       Impact factor: 21.198

Review 2.  Doyne lecture 2016: intraocular health and the many faces of inflammation.

Authors:  A D Dick
Journal:  Eye (Lond)       Date:  2016-09-16       Impact factor: 3.775

3.  Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis.

Authors:  T K Khera; D A Copland; J Boldison; P J P Lait; D E Szymkowski; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2012-05       Impact factor: 4.330

4.  MicroRNA-155 is induced during the macrophage inflammatory response.

Authors:  Ryan M O'Connell; Konstantin D Taganov; Mark P Boldin; Genhong Cheng; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-22       Impact factor: 11.205

5.  CD40 and tumour necrosis factor-α co-operate to up-regulate inducuble nitric oxide synthase expression in macrophages.

Authors:  Jose-Andres C Portillo; Luis Muniz Feliciano; Genevieve Okenka; Frederick Heinzel; M Cecilia Subauste; Carlos S Subauste
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

6.  Identification of novel dendritic cell populations in normal mouse retina.

Authors:  Heping Xu; Rosemary Dawson; John V Forrester; Janet Liversidge
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-04       Impact factor: 4.799

7.  The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases.

Authors:  D S Vinay; B S Kwon
Journal:  Clin Exp Immunol       Date:  2011-03-14       Impact factor: 4.330

8.  TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice.

Authors:  Thomas Calzascia; Marc Pellegrini; Håkan Hall; Laurent Sabbagh; Nobuyuki Ono; Alisha R Elford; Tak W Mak; Pamela S Ohashi
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

9.  Indirect action of tumor necrosis factor-alpha in liver injury during the CD8+ T cell response to an adeno-associated virus vector in mice.

Authors:  Matthew Giannandrea; Robert H Pierce; Ian Nicholas Crispe
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

10.  Anti-inflammatory effects of tumour necrosis factor (TNF)-alpha are mediated via TNF-R2 (p75) in tolerogenic transforming growth factor-beta-treated antigen-presenting cells.

Authors:  Sharmila Masli; Bruce Turpie
Journal:  Immunology       Date:  2009-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.